Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study

Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study

BackgroundThis study aimed to explore the clinical efficacy and safety of a modified FOLFOX6 (oxaliplatin + leucovorin + 5-fluorouracil) plus bevacizumab regimen after deep hyperthermia in advanced colorectal cancer.MethodsA total of 80 colorectal cancer patients treated at our hospital were selecte...

Full description

Bibliographic Details
Main Authors:	Guohu Han, Lihua Cui, Changchun Sun, Lijiang Yu, Shenzha Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Oncology
Subjects:	colorectal cancer bevacizumab deep hyperthermia chemotherapy treatment Karnofsky performance status
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1259713/full

Similar Items

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
by: Takao Takahashi, et al.
Published: (2022-09-01)

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
by: Pamela Baldin, et al.
Published: (2022-02-01)

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
by: Minna Kim, et al.
Published: (2023-12-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023-07-01)

Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
by: Masatsune Shibutani, et al.
Published: (2018-11-01)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
by: Diana Cornelia Moisuc, et al.
Published: (2023-02-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
by: Hélène Bellio, et al.
Published: (2021-10-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Variable Molecular Weight Polymer Nanoparticles for Detection and Hyperthermia-Induced Chemotherapy of Colorectal Cancer
by: Santu Sarkar, et al.
Published: (2021-09-01)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
by: Seijong Kim, et al.
Published: (2022-10-01)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
by: Toshimitsu Tanaka, et al.
Published: (2022-08-01)

High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer
by: Kei Furuya, et al.
Published: (2024-02-01)

Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy
by: Diana Cornelia Moisuc, et al.
Published: (2024-01-01)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
by: Ryo Nishikawa, et al.
Published: (2013-11-01)

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
by: Meiling Yang, et al.
Published: (2023-07-01)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
by: Antonia Martinetti, et al.
Published: (2014-08-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
by: Kunpeng Fang, et al.
Published: (2024-02-01)

FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
by: Yulian Li, et al.
Published: (2024-01-01)

Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
by: María Gaibar, et al.
Published: (2021-01-01)

Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis
by: Akshit Chitkara, et al.
Published: (2023-12-01)

Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
by: Yu Song, et al.
Published: (2024-02-01)

Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
by: Chao Chen, et al.
Published: (2022-04-01)

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
by: Hiroyuki Arai, et al.
Published: (2024-04-01)

In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
by: Michael Bordonaro, et al.
Published: (2016-05-01)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
by: Shen Zhao, et al.
Published: (2022-09-01)

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications
by: Shinji Rho, et al.
Published: (2023-03-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
by: Uysal Mukremin, et al.
Published: (2012-07-01)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
by: Andrew J. Wiele, et al.
Published: (2021-04-01)

Malignant Hyperthermia Like Manifestations during Management of Refractory Status Epilepticus
by: Deepti Srinivas, et al.
Published: (2023-03-01)

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
by: Min Yan, et al.
Published: (2024-03-01)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
by: Ioana Mihaela Dinu, et al.
Published: (2023-02-01)

The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis
by: Yurika Nakayama, et al.
Published: (2024-01-01)